Low-Dose Thalidomide for Prostate Cancer
Author Information
Author(s): Drake M J, Robson W, Mehta P, Schofield I, Neal D E, Leung H Y
Primary Institution: University of Newcastle
Hypothesis
Can low-dose thalidomide effectively reduce PSA levels in patients with androgen-independent prostate cancer?
Conclusion
Low-dose thalidomide can decrease PSA levels in nearly 40% of patients with androgen-independent prostate adenocarcinoma.
Supporting Evidence
- Six out of 16 men receiving thalidomide for at least 2 months showed a fall in their serum PSA levels by a mean of 48%.
- Three of the seven men who completed the full 6-month study showed a fall in absolute PSA by a mean of 50%.
- Adverse effects included constipation and sedation hangover, but quality of life scores remained stable.
Takeaway
This study tested a low dose of thalidomide to see if it could help men with a type of prostate cancer that doesn't respond to hormones. It worked for some men by lowering a specific cancer marker in their blood.
Methodology
Patients received 100 mg of thalidomide daily for up to 6 months, with monthly assessments of PSA levels and adverse effects.
Potential Biases
Potential bias due to the open-label design and lack of randomization.
Limitations
The study had a small sample size and lacked a control group.
Participant Demographics
Mean age was 71.1 years, with a range of 60 to 83 years; 65% had bony metastases.
Statistical Information
P-Value
0.06
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website